127 related articles for article (PubMed ID: 36372800)
1. DOK7 CpG hypermethylation in blood leukocytes as an epigenetic biomarker for acquired tamoxifen resistant in breast cancer.
Gowdini E; Aleyasin SA; Ramezani N; Nafisi N; Tutuni M
J Hum Genet; 2023 Jan; 68(1):33-38. PubMed ID: 36372800
[TBL] [Abstract][Full Text] [Related]
2. Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer.
Zhang Y; Zhang B; Fang J; Cao X
Int J Clin Exp Pathol; 2015; 8(8):9500-5. PubMed ID: 26464711
[TBL] [Abstract][Full Text] [Related]
3. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker.
Heyn H; Carmona FJ; Gomez A; Ferreira HJ; Bell JT; Sayols S; Ward K; Stefansson OA; Moran S; Sandoval J; Eyfjord JE; Spector TD; Esteller M
Carcinogenesis; 2013 Jan; 34(1):102-8. PubMed ID: 23054610
[TBL] [Abstract][Full Text] [Related]
5. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Martens JW; Nimmrich I; Koenig T; Look MP; Harbeck N; Model F; Kluth A; Bolt-de Vries J; Sieuwerts AM; Portengen H; Meijer-Van Gelder ME; Piepenbrock C; Olek A; Höfler H; Kiechle M; Klijn JG; Schmitt M; Maier S; Foekens JA
Cancer Res; 2005 May; 65(10):4101-17. PubMed ID: 15899800
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene.
Chang HG; Kim SJ; Chung KW; Noh DY; Kwon Y; Lee ES; Kang HS
J Mol Med (Berl); 2005 Feb; 83(2):132-9. PubMed ID: 15536519
[TBL] [Abstract][Full Text] [Related]
7. Epigenteic Alteration of
Moradi A; Aleyasin SA; Mohammadian K; Alizamir A
Iran J Biotechnol; 2022 Apr; 20(2):e3050. PubMed ID: 36337064
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
[TBL] [Abstract][Full Text] [Related]
9. Examination of methylation changes of
Shirkavand A; Boroujeni ZN; Aleyasin SA
Indian J Cancer; 2018; 55(4):366-371. PubMed ID: 30829272
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA.
Tang Q; Holland-Letz T; Slynko A; Cuk K; Marme F; Schott S; Heil J; Qu B; Golatta M; Bewerunge-Hudler M; Sutter C; Surowy H; Wappenschmidt B; Schmutzler R; Hoth M; Bugert P; Bartram CR; Sohn C; Schneeweiss A; Yang R; Burwinkel B
Oncotarget; 2016 Sep; 7(39):64191-64202. PubMed ID: 27577081
[TBL] [Abstract][Full Text] [Related]
11. The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives.
Sukocheva OA; Lukina E; Friedemann M; Menschikowski M; Hagelgans A; Aliev G
Semin Cancer Biol; 2022 Jul; 82():35-59. PubMed ID: 33301860
[TBL] [Abstract][Full Text] [Related]
12. PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy.
Fan Y; Xie G; Wang Z; Wang Y; Wang Y; Zheng H; Zhong X
Breast Cancer Res Treat; 2022 Feb; 192(1):33-42. PubMed ID: 34978016
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
15. Targeting HMG-CoA synthase 2 suppresses tamoxifen-resistant breast cancer growth by augmenting mitochondrial oxidative stress-mediated cell death.
Hwang S; Park S; Kim JH; Bang SB; Kim HJ; Ka NL; Ko Y; Kim SS; Lim GY; Lee S; Shin YK; Park SY; Kim S; Lee MO
Life Sci; 2023 Sep; 328():121827. PubMed ID: 37276910
[TBL] [Abstract][Full Text] [Related]
16.
Martín-Sánchez E; Mendaza S; Ulazia-Garmendia A; Monreal-Santesteban I; Córdoba A; Vicente-García F; Blanco-Luquin I; De La Cruz S; Aramendia A; Guerrero-Setas D
Clin Epigenetics; 2017; 9():7. PubMed ID: 28149335
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 promoter hypermethylation signature for early detection of breast cancer in the Vietnamese population.
Truong PK; Lao TD; Doan TP; Le TA
Asian Pac J Cancer Prev; 2014; 15(22):9607-10. PubMed ID: 25520075
[TBL] [Abstract][Full Text] [Related]
18. Methylation of progesterone receptor isoform A promoter in normal breast tissue: An epigenetic link between early age at menarche and risk of breast cancer?
Daraei A; Izadi P; Khorasani G; Nafissi N; Naghizadeh MM; Younosi N; Meysamie A; Mansoori Y; Nariman-Saleh-Fam Z; Bastami M; Saadatian Z; Zendehbad Z; Tavakkoly-Bazzaz J
J Cell Biochem; 2019 Aug; 120(8):12393-12401. PubMed ID: 30816620
[TBL] [Abstract][Full Text] [Related]
19. ELF5 and DOK7 regulation in anti-estrogen treated cells and tumors.
Fitzgerald LM; Browne EP; Christie KD; Punska EC; Simmons LO; Williams KE; Pentecost BT; M Jawale R; Otis CN; Arcaro KF
Cancer Cell Int; 2016; 16():8. PubMed ID: 26884724
[TBL] [Abstract][Full Text] [Related]
20. Investigating FGFR2 gene as a blood-based epigenetic biomarker in gastric cancer.
Aleyasin SA; Moradi A; Abolhasani N; Abdollahi M
Mol Biol Rep; 2024 Feb; 51(1):253. PubMed ID: 38302798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
